Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

from Entrepreneur https://ift.tt/3IbfNWX
via IFTTT